We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Protein Found to Suppress p53 in Cancer Cells

By Biotechdaily staff writers
Posted on 05 Mar 2007
For the first time, researchers have demonstrated that in human cancer cell lines, a protein known as HMGA1 inhibits p53-mediated apoptosis by interfering with the protein HIPK2, which helps p53 initiate apoptotic cell death.

Overexpression of HMGA1 has been associated with many types of cancer in humans. More...
Earlier research has shown that HMGA1 decreases the ability of p53 to inhibit cell death by a process known as apoptosis; inhibition of p53-mediated apoptosis causes tumors to develop in both animals and humans. However, precisely how HMGA1 mediates its pro-tumorigenic effects on p53 have not been clearly established.

In the study, which appears online on February 8, 2007, in advance of publication in the March 2007 print issue of the Journal of Clinical Investigation, Dr. Silvia Soddu and colleagues, from the Istituto Nazionale dei Tumori Regina Elena (Rome, Italy), found that overexpression of HMGA1 inhibited p53-mediated apoptosis and caused HIPK2 to relocate from the cell nucleus to the cytoplasm. Furthermore, expression of HIPK2 was required for HMGA1 to inhibit p53-mediated apoptosis.

Significantly, analysis of human breast cancer samples indicated that overexpression of HMGA1 correlated with the presence of HIPK2 in the cytoplasm and low levels of apoptotic cells, even in the presence of normal p53. This study therefore identifies a new process by which p53-mediated apoptosis can be suppressed, leading to the development of cancer.


Related Links:
Istituto Nazionale dei Tumori Regina Elena

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Clinical Informatics Platform
CLARION™
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.